ARKA Clinical Decision Support is designed to meet all four criteria for Non-Device CDS under FD&C Act §520(o)(1)(E) and FDA's January 2026 final guidance on Clinical Decision Support Software. Recommendations support, not replace, the clinician's judgment. Every recommendation is anchored in a published guideline or peer-reviewed source, with the basis available for independent review. CLIN emphasizes imaging appropriateness at order entry.
This recommendation is intended to support, not replace, clinical judgment. It is generated by ARKA, software designed to meet the four criteria for Non-Device Clinical Decision Support under FD&C Act §520(o)(1)(E) and FDA's final guidance on Clinical Decision Support Software (January 2026). The clinician is responsible for the final decision.
AIIE Evidence
RUQ ultrasound first for suspected cholecystitis; hepatobiliary scintigraphy (HIDA) when ultrasound is equivocal.
Ultrasound is the first-line study for right upper quadrant pain and suspected acute cholecystitis: it detects stones, wall thickening, pericholecystic fluid, and a sonographic Murphy sign. HIDA scanning adjudicates equivocal cases per Tokyo Guidelines diagnostic criteria.
The AIIE synthesis above is ARKA-authored; the sources below are the underlying external literature.
Journal of Hepato-Biliary-Pancreatic Sciences · 2018doi:10.1002/jhbp.515
American College of Radiology · 2024